1. In Vivo

Viz.ai: Precision Targeting Of Every Patient’s Medical “Moment Of Truth”

 
• By William Looney

Viz.ai is making artificial intelligence real and ready with an algorithm-based detection and diagnostics platform that is beating the clinical clock in fighting stroke. The start-up is now focused on positioning its joined-up AI software as standard-setter for broader patient engagement with big pharma on everything from participation in clinical trials to launching the next generation of high-touch specialty medicines.   

Artificial Intelligence
• Source: Shutterstock

In the health care business, where productivity is measured in patient lives saved, new technology breakthroughs from artificial intelligence (AI) ought to be a show stopper – so why is AI still stuck on the industry’s to “do list” of coming attractions? Investments in AI lag other sectors and tend to be confined to rote tasks that do not transform clinical practice and bolster the bottom line.

Analysts cite several factors behind this boxed in approach to AI, including health care’s conservative risk profile, especially with regard...

More from Innovation

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.